Hope · adult cancer patients (≥ 18 years)
1 finding from 1 review
Pain · adult cancer patients (≥ 18 years)
1 finding from 1 review
Fatigue · adult cancer patients (≥ 18 years)
1 finding from 1 review
Quality of life · adult cancer patients (≥ 18 years)
1 finding from 1 review
Anxiety · children with cancer
1 finding from 1 review
Depression · children with cancer
1 finding from 1 review
Complete recovery of facial nerve function at 12 months Defined as: complete recovery HB grade I. · Bell's palsy
It is very uncertain whether surgery for Bell's palsy changes complete recovery of facial nerve function at 12 months Defined as:… compared with medical treatment (oral prednisolone) or no treatment (very low certainty).
1 finding from 1 review
Complications and side effects · Bell's palsy
It is very uncertain whether surgery for Bell's palsy changes side effects and complications of treatmentMeasured by clinical… compared with medical treatment (oral prednisolone) or no treatment (very low certainty).
1 finding from 1 review
Complete recovery of facial nerve function at 12 months Defined as: complete recovery HB grade I. · Bell's palsy
It is very uncertain whether early surgery changes complete recovery of facial nerve function at 12 months Defined as:… compared with late surgery (very low certainty).
1 finding from 1 review
Complications and side effects · Bell's palsy
1 finding from 1 review
Primary outcome: complete clinical response (malar/discoid rash) · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher primary outcome: complete clinical response (malar/discoid rash) compared with placebo (low certainty).
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine probably leads to lower secondary outcome: clinical flare compared with placebo (moderate certainty).
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Complete response · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in primary outcome: complete clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review